

Oral Microbiome in Head and Neck Cancers: An Insight Are We Looking at a Step Beyond in Unraveling the Challenge?

Vaishnavi Vedam*, Sivadas Ganapathy

Senior Lecturer, Faculty of Dentistry, AIMST University, Kedah, Malaysia

doi [10.30699/ijp.2022.544926.2791](https://doi.org/10.30699/ijp.2022.544926.2791)

Article Info

Received 23 Dec 2021; Accepted 29 Jan 2022; Published Online 08 Mar 2022;

Corresponding Information:

Dr. Vaishnavi Vedam, Senior Lecturer, Faculty of Dentistry, AIMST University, Kedah, Malaysia
Email: vaishnavi@aimst.edu.my

Copyright © 2022. This is an open-access article distributed under the terms of the Creative Commons Attribution- 4.0 International License which permits share, copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, even commercially.

Dear Editor

Head and Neck Cancers (HNCs) contribute to one of the global health concerns and have been a challenge to oncologists for decades. Breakthroughs in research with evidence-based reports based on diagnostic and therapeutic approaches in clinical practice have been published to address patient concerns. Risk factors, namely age, sex, diet, habits, and geographical variations, pose an established link with the prevalence of HNCs. Despite ongoing studies in cancer, the 5-year survival rate of the patients remains <50% to date. This has encouraged the scientists to research other possible novel risk factors and prognosis transformers that could present as targets for preventive or therapeutic interventions.

“Oral Microbiome” refers to collective genomes of microorganisms that reside in the oral cavity (1). Microbiome in oral health may be taken as a reliable tumor biomarker in comparison to regional microbiome variation of the human body due to its low intra/inter microbial variations and effective growth due to comparatively stable and favorable oral environmental conditions. In March 2020, Human Oral Microbiome Database (HOMD) using Next Generation Sequencing Technology (HOMINGS) proposed 784 bacterial species with 1,567 genomes in the mouth (2).

Firmicutes phylum (266 taxa and 588 genomes) and a subset of this, the *Streptococcaceae* family (38 taxa and 200 genomes), have been considered to be of functional significance in oral diseases. A balanced state of the oral microbiome with systemic health, diet, and oral environmental factors (pH variability, saliva, and gingival crevicular fluid) contribute to the maintenance of the human oral ecosystem (3). Dysbiosis in this mechanism of host-microbial interactions is a proposed key factor in the occurrence of oral diseases. The relative importance of this in HNCs still needs to be explored.

Oral swab/ rinse and saliva samples are chair-side collection methods that are used routinely for microbial examination. Due to wide microbial variants and environmental influence, an accurate analysis method that has gained importance is ‘*Metagenomic studies*’ via 16s rRNA technology (4). This method categorizes and analyzes the microbial community, proteins, metabolites, and genetic material associated with these species. Altered microbial profiling in HNCs is shown in [Table 1](#) (5-6). Pictorial representation in [Figure 1](#) has been put forward to understand the role of oral microbiomes in HNCs based on the existing literature (7-8).

Table 1. Possible Oral Microbiome Involvement in HNCs (5-6)

| Microbial species | Taxonomical classification |
|-------------------|--|
| Bacteria | HIGH - Porphyromonas, Fusobacterium, Prevotella, Veillonella, Peptostreptococcus, Clostridium, Gemellaceae, Enterobacteriaceae, Leptotrichia, Lactobacillus, Corynebacterium, Actinomyces LOW - Haemophilus, Neisseria, Aggregatibacter, Firmicutes Haemophilus & Streptococcus (Altered levels based on species variation) |
| Viruses | HIGH - Herpes simplex virus (HHV 1&2), Epstein-Barr virus (EBV) Cytomegalovirus; Human papillomavirus (HPV); Hepatitis C Virus |
| Fungi | HIGH – Candida species – C.albicans, C. tropicalis, C. krusei, C. glabrata, C. parapsilosis |




Fig. 1. Possible and Proposed Pathophysiology of oral microbiomes in HNCs (7-8)

We would like to hypothesize that ‘dysbiosis in oral microbiomes also should be considered as a possible risk factor for HNCs’. Further research must be carried out to understand the mechanisms by which the tumor’s microbial community influences the behavior of the oral neoplasm. Despite the advances in salivary tumor biomarker diagnostics, the paradigm shift in oral microbiomes may offer new tumor biomarkers (proteins, metabolites, or genomes) that may reduce human biological variation for HNCs in the future. Over the regular radiotherapy and chemotherapy, adjuvant therapy using antimicrobial peptides, probiotics, and epidrugs may show substantial

improvement for cancer treatment, as they may intervene in cancer pathology, boosting the immune system, and lastly, alter the dysbiosis of oral microbiomes related to HNCs (9).

Acknowledgments

Nil.

Conflict of Interest

The authors declared no conflict of interest.

References

1. Al-Hebshi NN, Borgnakke WS, Johnson NW. The microbiome of oral squamous cell carcinomas: a functional perspective. *Curr Oral Health Rep.* 2019;6(2):145-60. [DOI:10.1007/s40496-019-0215-5]
2. Yuan S, Fang C, Leng WD, Wu L, Li BH, Wang XH, et al. Oral microbiota in the oral-genitourinary axis: identifying periodontitis as a potential risk of genitourinary cancers. *Mil Med Res.* 2021 Dec;8(1):1-4. [DOI:10.1186/s40779-021-00344-1] [PMID] [PMCID]
3. Tuominen H, Rautava J. Oral microbiota and cancer development. *Pathobiology.* 2021;88(2): 116-26. [DOI:10.1159/000510979] [PMID]
4. Deo PN, Deshmukh R. Oral microbiome and oral cancer–The probable nexus. *Journal of Oral and Maxillofacial Pathology: JOMFP.* 2020 May;24(2):361. [PMID] [PMCID] [DOI:10.4103/jomfp.JOMFP_20_20]

5. Purushottam L. Oral Microbiome and Response to Immunotherapy: Is It Time To Pay Attention? *On J Dent & Oral Health*. 2018; 1(1): OJDOH.MS.ID.000501. [[DOI:10.33552/OJDOH.2018.01.000501](https://doi.org/10.33552/OJDOH.2018.01.000501)]
6. Kusama K, Inoue H, Miyazaki Y, Kikuchi K, Sakashita H, Ochiai K. Microorganisms and cancer of the oral cavity. *Integr Cancer Sci Ther*. 2016;3:510-5. [[DOI:10.15761/ICST.1000200](https://doi.org/10.15761/ICST.1000200)]
7. Lim Y, Totsika M, Morrison M, Punyadeera C. Oral microbiome: a new biomarker reservoir for oral and oropharyngeal cancers. *Theranostics*. 2017;7(17):4313. [[DOI:10.7150/thno.21804](https://doi.org/10.7150/thno.21804)] [[PMID](#)] [[PMCID](#)]
8. Kadam S, Vandana M, Patwardhan S, Kaushik KS. Looking beyond the smokescreen: can the oral microbiome be a tool or target in the management of tobacco-associated oral cancer?. *E Cancer Med Sci*. 2021;15. [[DOI:10.3332/ecancer.2021.1179](https://doi.org/10.3332/ecancer.2021.1179)] [[PMID](#)] [[PMCID](#)]
9. Radaic A, Ganther S, Kamarajan P, Grandis J, Yom SS, Kapila YL. Paradigm shift in the pathogenesis and treatment of oral cancer and other cancers focused on the oralome and antimicrobial-based therapeutics. *Periodontology* 2000. 2021;87(1):76-93. [[DOI:10.1111/prd.12388](https://doi.org/10.1111/prd.12388)] [[PMID](#)] [[PMCID](#)]

How to Cite This Article

Vedam, V., Ganapathy, S. Oral Microbiome in Head and Neck Cancers: An Insight, Are We Looking at a Step Beyond in Unraveling the Challenge?. *Iran J Pathol*. 2022; 17(2): 238-240. doi: 10.30699/ijp.2022.544926.2791.